Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call 602-406-7437 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
Ivy Brain Tumor Center Announces Interim Results from a Phase 0 ‘Trigger’ Trial of Targeted Combination Therapy for Glioblastoma
The Ivy Brain Tumor Center has announced initial results from an ongoing, dual-drug Phase 0 study evaluating the tumor pharmacokinetics (PK) and tumor pharmacodynamics (PD) of abemaciclib, a selective CDK4/6-inhibitor, plus LY3214996, a selective ERK1/2 inhibitor, in recurrent glioblastoma patients.
After successful brain tumor surgery Warrington mom prepares for phase two of her journey
Warrington mother of two Louise Hulme, who flew to America for life-saving surgery to remove a stage four brain tumor, is now preparing for phase two of her journey.
Valley yoga studio raises awareness for brain tumor research
Last year, while serving on the frontlines against COVID-19, Ian Youngblood was diagnosed with glioblastoma. Now, Ian is back in Arizona and doing what he loves which includes teaching yoga classes, hiking and motivating everyone around him. On Saturday, May 29, Ian led a charity class in Scottsdale, AZ to support the cutting-edge research happening at the Ivy Brain Tumor Center.
Valley nurse and father diagnosed with brain cancer determined to ‘get better’
Just five weeks after his fourth child was born, Tim Jackson, a 43-year-old nurse from Arizona, was diagnosed with brain cancer. Tim and his wife, Amber, remain optimistic as he participates in a new Ivy Phase 0 clinical trial for newly diagnosed glioblastoma.
Family’s battle to raise £150,000 for mom’s brain tumor treatment in the United States
Louise and her husband Kev continue to manifest hope and overcome challenges in the face of a glioblastoma diagnosis. Traveling from the United Kingdom to the United States to participate in an Ivy Phase 0 clinical trial, Louise is determined to fight like a true brain tumor warrior.
Arizona Recognizes Brain Tumor Awareness Month
Governor Doug Ducey declared May to be Brain Tumor Awareness Month to promote education of the condition, recognize the medical professionals who combat the issue, highlight the significant progress in research, and honor the families who have been impacted.
CURE’s Clinical Trial Corner: April 2021
In the latest edition of CURE magazine's Clinical Trial Corner, the Ivy Center's first-in-human clinical trial of noninvasive sonodynamic therapy for recurrent brain cancer was highlighted.
Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer
The Ivy Center is pleased to announce the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy, a noninvasive drug-device combination developed by SonALAsense in collaboration with Insightec. This historic study aims to develop a nonsurgical treatment option for patients with recurrent glioblastoma and other high-grade gliomas.
Drug Researchers Need to Learn to “Fail Fast”
In this Techonomy exclusive from Dr. Nader Sanai, director of the Ivy Brain Tumor Center, he discusses the "fail fast" adage associated with Silicon Valley and the implications this method could have on the healthcare industry specifically, in clinical trials.
First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib in newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM). This is the first Phase 0 clinical trial open to newly diagnosed glioblastoma patients.